benphothiamine has been researched along with Diabetic Nephropathies in 8 studies
benfotiamine : A thioester that is a synthetic analogue of thiamine obtained by acylative cleavage of the thiazole ring and O-phospohorylation.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thiamine was found to be beneficial for reduction in albuminuria in a single study; however, there was lack of any improvement in kidney function or blood pressure following the use of vitamin B preparations used alone or in combination." | 4.91 | Vitamin B and its derivatives for diabetic kidney disease. ( Gor, D; Rangoonwala, AN; Raval, AD; Thakker, D; Walia, R, 2015) |
| "Patients with type 2 diabetes and urinary albumin excretion in the high-normal and microalbuminuric range (15-300 mg/24h) were randomized to receive benfotiamine (n = 39) or placebo (n = 43)." | 2.77 | Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. ( Alkhalaf, A; Bakker, SJ; Bilo, HJ; Gans, RO; Groenier, KH; Heeringa, P; Kleefstra, N; Navis, GJ; Schalkwijk, CG; Scheijen, JL, 2012) |
| "Patients with type 2 diabetes and UAE equivalent to 15-300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43)." | 2.75 | A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. ( Achenbach, U; Alkhalaf, A; Bakker, SJ; Bilo, HJ; Gans, RO; Kleefstra, N; Klooster, A; Mijnhout, GS; Navis, GJ; Slingerland, RJ; van Oeveren, W, 2010) |
| "Treatment with fenofibrate normalizes the altered lipid profile in diabetic rats, whereas benfotiamine treatment has no effect on lipid alteration in diabetic rats." | 1.35 | Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. ( Balakumar, P; Chakkarwar, VA; Singh, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Yako, H | 1 |
| Niimi, N | 1 |
| Kato, A | 1 |
| Takaku, S | 1 |
| Tatsumi, Y | 1 |
| Nishito, Y | 1 |
| Kato, K | 1 |
| Sango, K | 1 |
| Raval, AD | 1 |
| Thakker, D | 1 |
| Rangoonwala, AN | 1 |
| Gor, D | 1 |
| Walia, R | 1 |
| Schupp, N | 1 |
| Dette, EM | 1 |
| Schmid, U | 1 |
| Bahner, U | 1 |
| Winkler, M | 1 |
| Heidland, A | 1 |
| Stopper, H | 1 |
| Balakumar, P | 1 |
| Chakkarwar, VA | 1 |
| Singh, M | 1 |
| Alkhalaf, A | 2 |
| Klooster, A | 1 |
| van Oeveren, W | 1 |
| Achenbach, U | 1 |
| Kleefstra, N | 2 |
| Slingerland, RJ | 1 |
| Mijnhout, GS | 1 |
| Bilo, HJ | 2 |
| Gans, RO | 2 |
| Navis, GJ | 2 |
| Bakker, SJ | 2 |
| Groenier, KH | 1 |
| Heeringa, P | 1 |
| Scheijen, JL | 1 |
| Schalkwijk, CG | 1 |
| Babaei-Jadidi, R | 1 |
| Karachalias, N | 1 |
| Ahmed, N | 1 |
| Battah, S | 1 |
| Thornalley, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy[NCT00565318] | Phase 4 | 86 participants (Anticipated) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for benphothiamine and Diabetic Nephropathies
| Article | Year |
|---|---|
Vitamin B and its derivatives for diabetic kidney disease.
Topics: Albuminuria; Diabetic Nephropathies; Folic Acid; Humans; Pyridoxamine; Randomized Controlled Trials | 2015 |
3 trials available for benphothiamine and Diabetic Nephropathies
| Article | Year |
|---|---|
Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients.
Topics: Aged; Antimutagenic Agents; Cell Separation; Cells, Cultured; Diabetic Nephropathies; DNA Damage; Fe | 2008 |
A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy.
Topics: Adjuvants, Immunologic; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotens | 2010 |
Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy.
Topics: Aged; Biomarkers; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endoth | 2012 |
4 other studies available for benphothiamine and Diabetic Nephropathies
| Article | Year |
|---|---|
Role of pyruvate in maintaining cell viability and energy production under high-glucose conditions.
Topics: Adenosine Triphosphate; Animals; Cell Line; Cell Survival; Citric Acid Cycle; Diabetic Nephropathies | 2021 |
Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Chelating Agents; Diabetes Mellitu | 2009 |
Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine.
Topics: Albuminuria; Animals; Chelating Agents; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dos | 2003 |
Benfotiamine. Monograph.
Topics: Alcoholic Neuropathy; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Humans; | 2006 |